Drug Profile
Research programme: antizyme inducer - MediQuest Therapeutics
Alternative Names: MQX-3016Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MediQuest Therapeutics
- Class
- Mechanism of Action Ornithine decarboxylase antizyme stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Actinic keratosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Actinic keratosis in USA (Topical)
- 28 Aug 2012 Preclinical development is ongoing in USA
- 28 Aug 2012 Research programme: antizyme inducer - MediQuest Therapeutics is available for licensing as of 28 Aug 2012. http://www.mqti.com/